Literature DB >> 2545592

Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up.

S Toikkanen1, H Kujari.   

Abstract

Sixty-one mucinous carcinomas (MCs) of the female breast were followed-up for at least 18 years or until death (mean follow-up time, 26 years; median follow-up time, 23 years). The 61 MCs were compared with 441 unselected cases of breast carcinomas of all histologic types (reference carcinomas or RCs), which were follow-up for at least 21 years. When the MCs were divided into pure (PMCs) and mixed (MMCs) mucinous carcinomas, the 20-year cumulative corrected survival rate for operable cases in the PMC group was 79% +/- 11% (SE) and 28% +/- 13% for the MMC group. The difference is statistically significant (P less than .001). The PMCs had a significantly better survival rate (P less than .001) when compared with the RCs (20-year corrected survival rate, 41% +/- 3%). The survival rates for the MMCs and RCs did not differ significantly from each other. By Cox's multivariate analysis, pure histologic type and a tumor size less than 5cm were independent favorable prognostic factors in the MC group, but nodal status was closely related to the histologic type. Judging from the relative survival curves, no significant excess mortality of cancer occurred toward the end of the follow-up period in the PMC group.

Entities:  

Mesh:

Year:  1989        PMID: 2545592     DOI: 10.1016/0046-8177(89)90069-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

Review 1.  A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition.

Authors:  Hans-Peter Sinn; Hans Kreipe
Journal:  Breast Care (Basel)       Date:  2013-05       Impact factor: 2.860

2.  Residual mucin and response after neoadjuvant chemotherapy (NAC) in breast cancer.

Authors:  Maria Jove; Eldo Verghese; Nisha Sharma; Sally Lane
Journal:  BMJ Case Rep       Date:  2016-05-06

3.  Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes.

Authors:  Selman Emiroglu; Mustafa Tukenmez; Seyma Karakus; Hasan Karanlik; Semen Onder; Vahit Ozmen; Neslihan Cabioglu; Enver Ozkurt; Ravza Yilmaz; Mahmut Muslumanoglu
Journal:  Eur J Breast Health       Date:  2022-10-01

4.  Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears.

Authors:  V Kuenen-Boumeester; T H Van Der Kwast; H A Van Laarhoven; S C Henzen-Logmans
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

5.  Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.

Authors:  Purevsuren Jambal; Melanie M Badtke; J Chuck Harrell; Virginia F Borges; Miriam D Post; Grace E Sollender; Monique A Spillman; Kathryn B Horwitz; Britta M Jacobsen
Journal:  Breast Cancer Res Treat       Date:  2012-12-18       Impact factor: 4.872

Review 6.  [Invasive breast cancer: the current WHO classification].

Authors:  A Lebeau; M Kriegsmann; E Burandt; H-P Sinn
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

7.  Mucinous carcinoma of breast: Cytodiagnosis of a case.

Authors:  Sangeeta Sharma; Rani Bansal; Anjali Khare; Nivesh Agrawal
Journal:  J Cytol       Date:  2011-01       Impact factor: 1.000

8.  Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis.

Authors:  Soo Youn Bae; Min-Young Choi; Dong Hui Cho; Jeong Eon Lee; Seok Jin Nam; Jung-Hyun Yang
Journal:  J Breast Cancer       Date:  2011-12-27       Impact factor: 3.588

9.  Comparison of Clinical Features and Treatment Results of Mix Mucinous Carcinomas and Other Atypical Carcinomas of the Breast.

Authors:  Mustafa Gök; Uğur Topal; Bahadır Öz; Hülya Akgün; Alper Celal Akcan; Erdoğan Mütevelli Sözüer
Journal:  Eur J Breast Health       Date:  2019-10-01

10.  MicroRNA and histopathological characterization of pure mucinous breast carcinoma.

Authors:  Feng Zhou; Shuai Li; Hui-Min Meng; Li-Qiang Qi; Lin Gu
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.